Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.

Authors

Ying-Hsin Chen, Wei-Feng Li, Yen-Hao Chen, Ming-Chao Tsai, Yuan-Hung Kuo, Jing-Houng Wang, Chien-Hung Chen, Sheng-Nan Lu, Chih-Chi Wang, Chao-Hung Hung

Published in

Cancer immunology, immunotherapy : CII. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

The prognostic value of curative therapies-including liver transplantation, hepatectomy, and local ablation-in patients with advanced hepatocellular carcinoma (HCC) following atezolizumab plus bevacizumab treatment remains unclear. This study evaluated the feasibility of curative therapy and compared survival outcomes between patients who did and did not undergo curative interventions following atezolizumab plus bevacizumab, using a propensity score-matched (PSM) analysis.
We retrospectively analyzed 318 consecutive patients with advanced HCC who received atezolizumab plus bevacizumab between 2020 and 2024. Overall survival (OS) and progression-free survival (PFS) were defined as the primary and secondary endpoints, respectively. Survival outcomes were estimated using the Kaplan-Meier method and evaluated with multivariate Cox proportional hazards regression, modeling exposure to conversion curative therapy as a time-dependent covariate.
The objective response rate to atezolizumab plus bevacizumab was 34.6%. Thirty-six patients (11%) subsequently underwent curative therapy, including liver transplantation (n = 8, 2.5%), hepatectomy (n = 11, 3.5%), and local ablation (n = 17, 5.3%). Patients receiving curative therapy demonstrated significantly improved OS (p < 0.001) and PFS (p < 0.001) compared with those who did not, with benefits persisting after PSM analysis. Multivariate Cox regression identified curative therapy as an independent predictor of OS (hazard ratio [HR] 0.398; 95% confidence interval [CI] 0.179-0.885; p = 0.024).
In selected patients with advanced HCC who achieved disease control after atezolizumab-bevacizumab, conversion curative therapy was associated with favorable survival outcomes.

PMID:
42439929
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.